Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL) ...

Chronic lymphocytic leukemia (CCL) can affect each person differently. Current treatment options range from conservative monitoring to advanced drug therapies and novel agents under review in ...

The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic ...

As I prepare for treatment of my chronic lymphocytic leukemia, I reflect on the challenges of aging and side effects while ...

Leukemia warriors unlock miraculous healing powers as breakthrough treatments revolutionize cancer survival forever.

Practice-changing studies in both frontline CLL and relapsed/refractory disease, presented at ASH 2024, are discussed by Dr Jennifer Woyach.

Experts discuss the comparative efficacy of sonrotoclax plus zanubrutinib vs venetoclax in chronic lymphocytic leukemia ...

Following prescribed treatments is an essential part of managing a CLL diagnosis. But there’s more you can do to sustain your emotional well-being and get the most out of your treatment.

Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.

This article will describe each stage’s prognosis, symptoms, and treatment options. Once diagnosed, chronic lymphocytic leukemia is staged to determine how advanced the disease is and to help ...